WARS1

Across TCGA pan-cancer cohorts, WARS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated WARS1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher WARS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated WARS1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where WARS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.632	0.801	.017	12	view →
CCRCC	OS	Median	All	1.000	0.742	.023	10	view →
PDAC	OS	Tertile	IV	0.231	0.943	.024	6	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	5	view →
LSCC	OS	Tertile	II,III,IV	0.559	0.880	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

WARS1–GBM (DFS)

Open the GBM breakdown →